Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06829823 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Primary completion date: May 1, 2026 to Nov 2026 Start date: May 1, 2025 to Nov 2025 · Completion date: May 1, 2029 to Nov 2029v2 Show 2 more changesShow less
    • Start date: May 1, 2025 to Nov 2025
    • Completion date: May 1, 2029 to Nov 2029
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ImmunityBio, Inc.
33 trials monitored
See 2 trials at risk
Bladder Cancer
1,022 trials monitored
See 71 trials at risk
This is an open-label, phase 2, randomized study of intravesical N-803 plus BCG (experimental arm A) and intravesical N-803 plus gemcitabine (experimental arm B) in participants who have intermediate-risk Ta/T1 papillary disease. The primary objective of this study is to evaluate the efficacy of these experimental therapies without the need for surgical intervention by CR rate at month 3 or month 6 (for re-inducted participants).
Trial Details
NCT Number NCT06829823
Lead Sponsor ImmunityBio, Inc.
Conditions Non-muscle Invasive Bladder Cancer (NMIBC)
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov